ArticlePloS one2025
Transplacental transfer of maternal SARS-CoV-2 antibodies in dichorionic and monochorionic twin pregnancies.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMaternal immunization relies on active transplacental transfer of immunoglobulin G. However, very little is known about the efficacy of maternal immunization in the setting of multiple gestation. We aimed to investigate transplacental transfer of maternal antibody in pregnancies with multiple gestation including mono- and dichorionic pregnancies by evaluating anti-Spike antibody transfer at delivery.
methodsWe conducted a cohort study among individuals with singleton or twin pregnancies who received ≥ 2 doses of an mRNA COVID-19 vaccine before delivery. We tested paired maternal and cord blood samples for anti-Spike antibody levels via Roche Elecsys® immunoassays and used linear regression to evaluate associations between pregnancy type and anti-Spike antibody levels. We included as covariates gestational age at birth, timing of last vaccine dose, number of vaccine doses, and small for gestational age birth weight.
resultsBetween 2021-2023, we tested paired maternal and cord samples for anti-Spike antibody from 362 singleton pregnancies and 36 twin pregnancies, of which 12 and 24 were monochorionic and dichorionic, respectively. After adjusting for covariates, maternal and cord anti-Spike antibody concentrations were significantly lower in twin pregnancies compared to singleton pregnancies (beta:-0.91, 95% Confidence Interval [CI]: -1.62,-0.19; p = 0.01. beta -1.20, 95% CI: -2.36,-0.04; p = 0.04), however there was no difference in cord:maternal antibody ratios. After adjusting for covariates, there was no difference in maternal and cord antibody concentrations between dichorionic and monochorionic pregnancies, however, cord:maternal antibody ratios remained significantly lower in monochorionic compared to dichorionic pregnancies (beta:-0.49; 95% CI: -0.86,-0.13; p = 0.01).
conclusionsTwin and singleton infants have similar cord:maternal maternally derived SARS-CoV-2 antibody ratios after maternal COVID-19 vaccine although maternal and cord antibody concentrations are lower in infants from twin pregnancies and specifically antibody transfer is less efficient in monochorionic pregnancies. Further research is needed to investigate impaired transplacental IgG transfer in high-risk pregnancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.